FDA U-turns to approve Sarepta’s Vyondys 53 in Duchenne muscular dystrophy
pharmafile | December 13, 2019 | News story | Medical Communications, Sales and Marketing | FDA, Vyondys 53, pharma, sarepta
The FDA has surprised industry pundits by choosing to approve Sarepta’s Vyondys 53 under an accelerated pathway for the treatment of Duchenne muscular dystrophy (DMD) just four months after it announced it would be rejecting the drug.
Doubly surprising was the fact that there had been no reports that the company had resubmitted its application for the drug. The application covers the approximately 8% of DMD patients with a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
This decision was based on data showing that Vyondys 53 increased dystrophin production in skeletal muscle in some patients that is “reasonably likely to predict clinical benefit in patients with DMD who have a confirmed mutation of the dystrophin gene amenable to exon 53 skipping”; the drug increased dystrophin levels to 1.02% of normal from 0.10% at baseline following 48 weeks or longer of treatment.
However, its ability to improve motor function has not yet been confirmed; the FDA has considered these potential risks in its ruling, and has asked Sarepta to provide further data on the drug’s efficacy.
“The FDA recognises the urgent need for new medical treatments for serious neurological disorders and we have a long-standing commitment to working with researchers, drug companies and patients to facilitate the development and approval of treatments for rare diseases,” said Dr Billy Dunn, acting Director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research. “With today’s accelerated approval, patients with Duchenne muscular dystrophy — a rare and devastating disease — who have a confirmed mutation of the dystrophin gene amenable to exon 53 skipping will now have available the first treatment targeted specifically for this disease subtype. Use of the accelerated approval pathway will make Vyondys 53 available to patients based on initial data and we look forward to learning more about the drug’s clinical benefit from the ongoing confirmatory clinical trial.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …
